$5.22
3.69% yesterday
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US5393192027
Symbol
LIXT

Lixte Biotechnology Holdings Inc Stock price

$5.22
+1.93 58.66% 1M
+3.88 289.55% 6M
+3.19 157.18% YTD
+3.38 183.70% 1Y
+0.22 4.40% 3Y
+4.04 342.37% 5Y
+3.66 234.62% 10Y
+0.72 16.00% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.20 3.69%
ISIN
US5393192027
Symbol
LIXT
Industry

Key metrics

Basic
Market capitalization
$23.8m
Enterprise Value
$22.9m
Net debt
positive
Cash
$890.0k
Shares outstanding
2.8m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
36.6
Financial Health
Equity Ratio
72.2%
Return on Equity
-433.5%
ROCE
-473.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
- | -
EBIT
$-3.1m | -
Net Income
$-3.1m | -
Free Cash Flow
$-2.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
23.5% | -
Net Income
23.3% | -
Free Cash Flow
24.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
0.5%
Employees
2
Rev per Employee
$0.0
Show more

Is Lixte Biotechnology Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Financial data from Lixte Biotechnology Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.41 3.41
34% 34%
-
- Research and Development Expense 0.55 0.55
10% 10%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.08 -3.08
24% 24%
-
Net Profit -3.09 -3.09
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lixte Biotechnology Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lixte Biotechnology Holdings Inc Stock News

Neutral
Accesswire
8 days ago
BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight shifts to the science itself.
Neutral
Accesswire
8 days ago
BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT) had other plans.
Neutral
GlobeNewsWire
14 days ago
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions.
More Lixte Biotechnology Holdings Inc News

Company Profile

Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.

Head office United States
CEO Bastiaan Baan
Employees 2
Founded 2005
Website lixte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today